The MedAdvisor Ltd (ASX: MDR) share price has been a positive performer on Monday morning.
At the time of writing, the medication management platform provider’s shares are up 2.5% to 40 cents.
Why is the MedAdvisor share price pushing higher?
Investors have been buying the company’s shares this morning after the release of a trading update.
According to the release, MedAdvisor’s US subsidiary, Adheris, has been performing better than it anticipated since being acquired on 17 November.
In light of this, the company is expecting Adheris’ revenue to be higher than the guidance it previously provided.
For the period 1 July to the end of November, Adheris achieved revenue of US$14 million. This compares to half year revenue guidance of US$13.8 million.
This appears to have been driven partly by the signing of a one-year deal with a major US biopharmaceutical company at the end of last month. The unnamed US$70 billion biotech giant is leveraging its data and analytics platform to target patient awareness and adherence across the Adheris network.
FY 2021 guidance upgrade.
Pleasingly, management expects this outperformance to continue in the second half and has lifted its full year Adheris guidance.
For the 12 months, the company was forecasting Adheris to deliver revenue of US$26.4 million. It now expects this to be 7.5% higher at US$28.4 million. Management advised that this represents 12.2% growth year on year.
MedAdvisor’s CEO and Managing Director, Robert Read, commented: “We’re pleased to confirm that trading for the half-to-date for our newly-acquired Adheris subsidiary has exceeded $14m USD with one month of trading to go.”
“Our investment thesis and diligence had sought to confirm that the Adheris business was delivering growth which could be accelerated with MedAdvisor’s technology across the substantial scale the business had built over the last 25 years. We are pleased to see the core business improve its growth trajectory and look forward to investing in growth initiatives that will accelerate this even further,” he concluded.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting…
Because ‘Doc’ Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
See how you can find out the name of this stock
Returns as of 6th October 2020
More reading
- MedAdvisor (ASX:MDR) share price shoots up 8% today. Here’s why.
- 2 ASX small cap healthcare shares growing quickly
- Why Afterpay, Goodman, MedAdvisor, & PointsBet shares are dropping lower
- Why the MedAdvisor (ASX:MDR) share price jumped 9% on Friday
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of MedAdvisor. The Motley Fool Australia has recommended MedAdvisor. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why the MedAdvisor (ASX:MDR) share price is pushing higher today appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/33RsaFb
Leave a Reply